Ward, Thomas
Brown, Tray
Lewis, Ruth D.
Kliess, Melodi Kosaner
de Arellano, Antonio Ramirez
Quinn, Carol M.
Funding for this research was provided by:
Vifor Pharma
Article History
Accepted: 10 July 2022
First Online: 4 August 2022
Declarations
:
: This work was supported by Vifor Pharma Ltd who provided support for data analysis, model development and medical writing for this study, in accordance with Good Publication Practice (GPP3) guidelines (ExternalRef removed).
: Antonio Ramirez de Arellano and Carol M. Quinn are employees of Vifor Pharma Ltd. Thomas Ward, Tray Brown, Ruth D. Lewis and Melodi Kosaner Kliess are employees of HEOR Ltd. HEOR Ltd received fees from Vifor Pharma Ltd in relation to this study.
: Not applicable.
: Not applicable.
: Not applicable.
: All data and material relevant to the analysis are presented in the outlined publication or supplementary material, with the exception of the model itself. The model used in this study was provided to the journal’s peer reviewers for their reference when reviewing the manuscript.
: The authors will respond to all enquiries regarding the details of the analysis should these not have been answered by the information provided in the methods section.
: TW, ARdA, CMQ and TB conceptualised and designed the study. TW and MKK were responsible for the data analysis. All authors contributed to the interpretation of the results, preparation and review of the manuscript, and approval of the final manuscript for publication.